BRCA2 and breast cancer: Due to the early age of breast cancer diagnosis, along with the distinct immunophenotype, the patient fulfilled the updated NCCN guidelines (http://www.nccn.org/) and was therefore tested for deleterious mutations in BRCA1 and BRCA2 genes.